LevineMNRaskobGLandefeldSKearonC. Hemorrhagic complications of anticoagulant treatment (suppl). Chest2001;119:108S–21S.
2.
DrakosPENaglerAOrRGillisSSlavinSEldorA. Low-molecular-weight heparin for Hickman catheter-induced thrombosis in thrombocytopenic patients undergoing bone marrow transplantation. Cancer1992;70: 1895–8.
3.
SakuragawaNHasegawaHMakiMNakagawaMNakashimaM. Clinical evaluation of low-molecular-weight heparin on disseminated intravascular coagulation. Thrombosis Research1993;72: 475–500.
4.
GillisSDannEJEldorA. A low-molecular-weight heparin in the prophylaxis and treatment of disseminated intravascular coagulation in acute leukemia. Eur J Haematol1995;54: 59–60.
5.
NieuwenhuisHKSixmaJJ. Treatment of disseminated intravascular coagulation with low-molecular-weight heparin. Cancer1986;58: 761–4.
6.
OrRNaglerAShpilbergOEladSNaparstekEKapelushnikJLow-molecular-weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation1996;7: 1067–71.
7.
ShenZXBasaraNXiXDCaenJMaffrandJPPascalMFraxiparin, a low-molecular-weight heparin, stimulated megakaryocytopoiesis in vitro and in vivo in mice. Br J Haematol1994;88: 608–12.
